M. Pao MD
paom@mail.nih.gov
June 2010
Psychopharmacologic Transitions References
DeJong M, Fombonne E: Citalopram to treat depression in pediatric oncology. J Child Adolesc
Psychopharm 17:371-377, 2007.
Dinndorf PA, McCabe MA, Frierdich S: Risk of abuse of diphenhydramine in children and adolescents
with chronic illnesses. J Pediatr 133:293-295, 1998.
Fox E, Balis F: Drug therapy in neonates and pediatric patients. In Atkinson AJ, Abernathy DR, Daniels
CE, et al (Eds.), Principles of Clinical Pharmacology, 2nd ed (293-305). San Diego, CA: Academic Press,
2007.
Galloway KS, Yaster M: Pain and symptom control in terminally ill children. Pediatr Clin North Am
47:711-746, 2000.
Gleason MM, Egger HL, Emslie GJ, et al: Psychopharmacological treatment for very young children:
contexts and guidelines. J Am Acad Child Adolesc Psychiatry 46:1532-1572, 2007.
Gothelf D, Rubinstein M, Shemesh E, Miller O, Farbstein I, Klein A, Weizman A, Apter A, Yaniv I: Pilot
study: fluvoxamine treatment for depression and anxiety disorders in children and adolescents with
cancer. Journal of the American Academy of Child and Adolescent Psychiatry 44:1258-1262, 2005.
Haddad PM, Dursun SM: Neurological complications of pyschiatric drugs: clinical features and
management. Hum Psychopharmacol 23 (suppl):15-26, 2008.
Hilt RJ, Woodward TA: Agitation treatment for pediatric emergency patients. J Am Acad Child Adolesc
Psychaitry 47:132-138, 2008.
Kersun LS, Elia J: Depressive symptoms and SSRI use in pediatric oncology patients. Pediatr Blood Cancer
49(7):881-887, 2007.
Kersun LS, Kazak AE: Prescribing practices of selective serotonin reuptake inhibitors (SSRIs) among
pediatric oncologists: A single institution experience. Pediatric Blood and Cancer 1-4, 2005.
Konsman JP, Parnet P, Dantzer R: Cytokine-induced sickness behavior: mechanisms and implications.
Trends in Neuroscience 25:154-159, 2002.
McEwen B, Lasley EN: The End of Stress As We Know It. Washington, D.C.: The Dana Press, Joseph Henry
Press, 2002.
Miller AH, Maletic V, Raison CL: Inflammation and its discontents: the role of cytokines in the
pathophysiology of major depression. Biol Psychiatry 65(9):732-741, 2009.
Pao M, Ballard EB, Rosenstein DL, Wiener L, Wayne AS: Psychotropic medication use in pediatric
patients with cancer. Arch Pediatr Adolesc Med 160:818-822, 2006.
M. Pao MD
paom@mail.nih.gov
June 2010
Portteus A, Ahmad N, Tobey D, Leavey P: The prevalence and use of antidepressant medication in
pediatric cancer patients. J Child Adolesc Psychopharm 16:467-473, 2006.
Reinblatt SP, Riddle MA: The pharmacological management of childhood anxiety disorders: a review.
Psychopharmacology (Berl) 191:67-86, 2007.
Robertson L: When should young people with chronic rheumatic disease move from paediatric to
adult-centred care? Best Pract Res Clin Rheumatol 20(2):387–97, 2006.
Spady DW, Schopflocher DP, Svenson LW, et al: Medical and psychiatric comorbidity and health care use
among children 6 to 17 years old. Arch Pediatr Adolesc Med 159:231-237, 2005.
Stoddard FJ, Usher CT, Abrams AN: Psychopharmacology in pediatric crticial care. Child Adolesc
Psychiatr Clin N Am 15:611-655, 2006.
Turkel S, Pao M: Late consequences of chronic pediatric illness. Psych Clin NA 30:819-835, 2007.
Waslick B: Oxcarbazepine and pediatric bipolar disorder. Am J Psychiatry 163:1179-1186, 2006.
Zito JM, Safer DJ, DosReis S, et al: Psychotropic practice patterns for youth: a 10-year perspective. Arch
Pediatr Adolesc Med 157:17-25, 2003.